SuperMeat secures US$6 million Series A-4 funding to advance cultivated chicken launch in Switzerland

SuperMeat has completed an initial closing of its Series A-4 financing round, securing US$6 million as part of a targeted US$10 million raise to support the commercialization of its cultivated chicken technology and planned market entry in Switzerland.

SuperMeat raised US$6 million in an initial close of its targeted US$10 million Series A-4 financing round.
The company said the funding would support a licensing-led commercialization strategy and a planned Swiss market launch.
SuperMeat expanded collaborations with Ajinomoto and Migros subsidiary Micarna while advancing scale-up and regulatory milestones.

The round included participation from existing investors Agronomics, Milk & Honey Ventures and New Agrarian Company Limited, an affiliated company of Agronomics. Agronomics contributed US$5 million through the issuance of new shares, while New Agrarian invested US$1 million in cash.

The financing marked the latest step in SuperMeat’s push toward commercial deployment of cultivated chicken after a series of technical and manufacturing milestones over the past two years.

The company reported that the funding would support its licensing-led commercialization strategy, with Switzerland identified as its first target launch market. SuperMeat said near-term priorities included process verification at commercial scale, regulatory preparation and consumer-facing validation studies.

As part of those efforts, the company entered into an R&D and technology development framework agreement with Ajinomoto and extended its collaboration agreement with Micarna, a subsidiary of Swiss retail group Migros. Planned activities included joint product development with Ajinomoto and a consumer validation study led by Migros in Switzerland ahead of a planned Swiss regulatory submission.

The company is also progressing a reorganization under a UK holding company structure as part of its international expansion plans.

The latest raise followed SuperMeat’s November 2025 SAFE financing, in which the company secured US$3.5 million to accelerate its European commercialization strategy after reporting progress toward cost parity for cultivated chicken production. That round formed part of a wider US$4.5 million SAFE structure capped at a post-money valuation of US$35 million.

At the time, SuperMeat said the financing would support industrial production scale-up and commercial partnerships across Europe. Agronomics invested US$2 million in the SAFE round through a combination of cash and new shares, while Milk & Honey Ventures also participated.

Speaking following the 2025 SAFE raise, SuperMeat Co-founder & CEO Ido Savir said the company had shifted its focus toward commercial execution after advances in production efficiency. “We’re honored by Agronomics’ continued support and confidence in our work,” he said. “Over the past year we have made substantial advancements across our production platform, for the first time, making cultivated chicken production commercially viable, and are now focused on translating these achievements into commercial launch.”

“This investment supports our progress toward bringing cultivated chicken to market with partners who understand how significant this category can become as demand and expectations evolve.”

One of the company’s most closely watched milestones came in November 2024, when SuperMeat announced that it had reached a production cost estimate of approximately US$11.79 per pound for 100% cultivated chicken at scale. The process produced cultivated chicken comprising 85% muscle and 15% fat without blending in plant-based ingredients to lower costs.

The benchmark placed SuperMeat broadly in line with premium pasture-raised chicken pricing in the United States and represented one of the sector’s clearest public signals around cultivated meat cost reduction.

Savir later told Protein Production Technology International that affordability and industrial efficiency remained central to the company’s strategy.

“Our vision is to make cultivated meat a mainstream choice, broadening protein sources while reducing dependence on traditional agriculture,” he said.

“By producing animal meat through an industrial, resource-efficient, and sustainable process – without compromising affordability – we can meet consumer demand while driving a scalable alternative.”

SuperMeat has also focused heavily on manufacturing optimization and bioprocessing partnerships as it works toward industrial scale.

In February 2025, the company partnered with bioprocessing specialist Stämm to integrate continuous bioprocessing technology into cultivated meat production. The collaboration, supported by mutual investor Varana Capital, aimed to assess how Stämm’s bubble-free continuous bioreactor technology could improve productivity, tissue formation and manufacturing economics.

The companies said the partnership would focus on muscle fiber growth, elongation and fusion into mature muscle tissue, alongside adipocyte formation required for whole-cut cultivated meat products.

At the time, Savir said the collaboration reflected the importance of combining complementary technologies across the cultivated meat ecosystem.

“This partnership demonstrates how complementary technologies can accelerate progress in the cultivated meat industry,” he said. “By uniting our cell-based production expertise with Stämm’s bioprocessing innovations, we can further optimize muscle and fat tissue formation, bringing cultivated whole-cut meat products closer to commercial reality.”

SuperMeat also said the partnership would support development of scalable production models and evaluate opportunities to reduce media costs, one of the industry’s largest economic bottlenecks.

Alongside manufacturing progress, the company has continued to emphasize sustainability metrics. In March 2024, SuperMeat published a life-cycle analysis conducted by CE Delft estimating that its cultivated chicken could generate approximately 50% lower carbon emissions than conventionally farmed chicken.

The company has additionally expanded its international partnership network in preparation for commercialization. SuperMeat is a founding member of Cellular Agriculture Europe and has formed partnerships with Germany’s PHW Group as well as Migros in Switzerland to support future production and distribution activities.

Jim Mellon, Executive Chair of Agronomics, said the latest financing reflected continued confidence in SuperMeat’s commercialization progress.

“SuperMeat's Series A-4 financing marks an important step in its development and reflects continued progress towards commercial launch,” he said.

“Having supported the business since 2020, we believe the company is well positioned to advance its licensing-led strategy and we are pleased to continue backing the team through this next phase of growth.”

Agronomics first invested in SuperMeat in December 2020 and, following the latest financing, will have invested a total of £15.2 million (US$20.2 million) in the company. Following completion of the round, Agronomics will hold approximately 27.8% of SuperMeat on a fully diluted basis.

SuperMeat currently operates a 200-liter pilot production facility and has continued working with partners on application testing and manufacturing scale-up as the cultivated meat sector increasingly shifts its focus from proof-of-concept development toward regulatory readiness, cost reduction and commercial deployment.